The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

5.1K views · 261 reactions | Watch our Facebook Live now! Listen as FORCE founder Sue Friedman and Oncotype DX® patient ambassador Punita K. talk about why advocating for yourself while navigating cancer matters and how genomic and genetic tests can help. | Exact Sciences | Facebook